samedan logo

 
 
spacer
home > pmps > spring 2009 > from cip13 to serialisation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

From CIP13 to Serialisation

Pharmaceutical manufacturers in Europe are facing many new challenges related to their product packaging operations, and one of the most problematic is the need to integrate sophisticated codes, or to serialise product packaging. Regulatory requirements such as the French CIP13 coding are forcing changes to packaging lines throughout Europe. Many countries are preparing to adopt similar requirements for pharmaceutical tracking and reimbursement initiatives. While deadlines and mandates are constantly changing, manufacturers must make crucial decisions with regard to their packaging operations. Industry leaders recognise that individual factors, such as country-specific regulatory requirements, may drive local projects, but the adoption of sophisticated coding or product serialisation requires an overall strategy.

Companies must consider what, when and where information should be added to product packaging. These decisions may affect how a product is packaged, at what location it is packaged, and how the product is distributed into the supply chain. These are business decisions that require cross-functional teams to formulate strategies and to implement plans. These teams should consider the implications on packaging resources, product availability and sourcing, supply chain and trade strategies, and information systems architecture and processes.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.

spacer
With more than 25 years of sales, marketing and general management experience in business-to-business environments, Joe Ringwood plays a key role in Systech’s business operations as COO. He is tasked with expanding Systech’s market position as a provider of packaging execution systems to pharmaceutical companies. Joe is responsible for directing strategies for growth, both domestically and internationally, and to encourage, business and technology partner relationships. His current responsibilities include: oversight of domestic and international sales teams, development and execution of Systech’s marketing, management of the professional services team, new product development, strategic business development and management of central engineering.
spacer
Joe Ringwood
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ProBioGen and Minapharm Pharmaceuticals incorporate MiGenTra GmbH – A Healthcare Transforming Medicines Company

Berlin, Germany and Cairo, Egypt, May 27, 2021: ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra" with headquarters in Berlin and access to a site in Cairo, which will house its principal manufacturing plant.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement